CT Gov. Ned Lamont’s administration has rejected proposals that would have allowed Connecticut to stockpile mifepristone, an abortion drug ahead of the Trump administration taking office.

The colorant was banned from cosmetics and non-oral medications decades ago because a study showed it caused cancer when eaten by rats. But it kept appearing on the ingredient lists of popular snack foods and other grocery products because it remained approved for use until now.

The Food and Drug Administration said Wednesday it’s banning the use of Red No. 3, a synthetic dye that gives food and drinks their bright red cherry color but has been linked to cancer in animals.

The Food and Drug Administration has said it is banning the use of Red No. 3, a synthetic dye that has long been used in the U.S. to color certain foods, such as candies and colored beverages, as well as some oral medicines and supplements.

The FDA ha banned Red No. 3 from food and drugs due to its potential cancer risk. A Yale professor and toxicologist and others explain the healthy risk.

Over 700 signatures on a public letter to U.S. Senate to reject RFK Jr's nomination to the Health and Human Services department.

Drugs like Ozempic and Wegovy are now costing Connecticut taxpayers about $60 million this year and that figure could rise next year.

The Food and Drug Administration said the recall impacts two-pound logs ... The FDA said the food was primarily sold in Connecticut, Maryland, Massachusetts, New York, Pennsylvania, and Virginia between Thursday, July 18, and Friday, July 26, 2024.

Products were recalled because of concerns over salmonella and listeria contamination and undeclared allergens.

The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started, so current drug prices are unaffected.

A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, contraindications.

Several states, including Massachusetts, began stockpiling the drug after a federal court ruling in Texas blocked the FDA’s approval of mifepristone in April 2023. Last June, the Supreme Court dismissed that case based on legal standing, preserving access for now.